📣 We are excited to be presenting a webinar on @BioBRIC! .In this session, we will address key challenges and considerations for adapting therapies originally designed for B-cell malignancies to #autoimmune diseases. Learn more and register here: #Bcell

#STEAP1 is an ideal target for precision #immunotherapy. At #GemPharmatech, we’ve established a comprehensive in vitro and in vivo evaluation platform tailored for STEAP1-targeting T-cell engagers (#TCEs). Contact us to learn more: .#CancerResearch #TCE

#ALS remains one of the most challenging #neurodegenerative diseases to study and treat. This on-demand webinar covers how mouse models recapitulate key aspects of ALS pathology, providing powerful tools to investigate disease mechanisms.

Great time at s Vendor Discovery Night in San Francisco! Thank you to @scientist_com for bringing together a fantastic group of scientists—and to all the attendees who stopped by to learn how #GemPharmatech is accelerating breakthroughs!.#LifeScience

In #cardiovascular disease research, the right animal models can make all the difference. Our B6-hRXFP1 humanized mouse model enables direct #invivo testing of RXFP-1 targeted therapeutics, delivering results that are highly translatable to human biology.

Big news! We will be exhibiting to Festival of Biologics Basel 2025! Dive into breakthrough therapies and next-gen biotech with us at booth #266. Innovation awaits! 🔥. 🎟️ Register before Sept. 5 and save!. #FestivalOfBiologics #GemPharmatech #antibody

【セミナー開催のお知らせ】GemPharmatechが湘南iParkに登場！🚀 .We will be hosting an exclusive seminar at @shonanipark in Japan, featuring three experts who will dive into cutting-edge research pipelines across #oncology, #autoimmune diseases, and #neurological disorders!.#biotech

Join us for a live webinar on August 26 as we explore how our #mousemodels faithfully recapitulate key aspects of Amyotrophic Lateral Sclerosis (#ALS) pathology, providing powerful tools to support #preclinical drug development. Register now: . #Neuro

We’re live at #KSBNS2025! Earlier today, Dr. Rikki Feng presented GemPharmatech’s novel FAD3T model, which incorporates a triple mutation design to better replicate human #Alzheimer’s disease (#AD) pathology — bridging critical gaps in #preclinical AD modeling. #KSBNS @KsbnsNeuro

We had an amazing time this week connecting with researchers on campus at @nyugrossman, @IcahnMountSinai, and @RockefellerUniv/@WeillCornell to discuss how our genetically engineered #mousemodels (#GEMMs) are helping push the boundaries of discovery. #Research #Innovation

Through case studies with ABBV-399 and DS-8201a, we demonstrate how our in vitro evaluation platform generates actionable, mechanistic data that de-risks #preclinical programs. Read the full blog to explore how GemPharmatech can advance your #ADC pipeline:

Last week, our team attended the RTB-AALAS Vendor Show and Business Meeting in North Carolina’s Research Triangle. Great to connect with and get to know fellow animal-people in the area!.#AALAS #GemPharmatech #Innovation #Biotech #Reaserch #AnimalModels #MouseModels

GemPharmatech is heading to the 2025 ESC Congress (@escardio) together with World Congress of Cardiology! .Join us in Madrid as we showcase the latest advancements in #cardiovascular research and innovative #preclinical solutions. #Cardiology #ESC2025 #ESCCongress #WCCardio

In November 2024, AMG 509 (#Xaluritamig), the world’s first #STEAP1-targeting T-cell engager (#TCE) entered Phase III trials. At #GemPharmatech, we’ve established a comprehensive in vitro and in vivo evaluation platform tailored for STEAP1-targeting TCEs.

Join us for an exclusive luncheon seminar at #KSBNS2025! 🧠.Dr. Rikki Feng will discuss our newly developed FAD3T mouse model — a transformative tool designed to accelerate #Alzheimer’s disease research!. Don’t forget to visit Booth #95 to connect with our team!. #Neuroscience

#ACVR1C, a key member of the TGF-β superfamily, has gained attention as a promising therapeutic target for #metabolic disorders. To support the development of #RNA therapeutics, GemPharmatech has created the B6-hACVR1C humanized mouse model. Learn more:

#GemPharmatech will be attending the @KsbnsNeuro 28th Annual Meeting of the Korean Society for Brain and Neural Sciences (#KSBNS2025) from August 24 to 27, 2025, in Incheon, Korea!. Visit booth #95 to connect and discover how we can advance your #neuroscience research. #Neuro

Join our webinar on August 26 to explore how our #mousemodels faithfully recapitulate key aspects of Amyotrophic Lateral Sclerosis pathology, providing powerful tools to support #preclinical #drugdevelopment. 🔗 Register now: . #ALSResearch #Neuroscience

Last week, our business development team completed training at our Chinese headquarters in Nanjing! A big welcome to our new team members!.Together, our scientists and BD team will help bring #GemPharmatech’s expertise across all disease areas to the greater scientific community.

GLP-1 receptor agonists are currently leading the way in #obesity management therapies. #GemPharmatech has developed a humanized B6-hGLP-1R mouse model to evaluate small-molecule incretins and combination therapies for #metabolic disease. #ObesityResearch